



Medical benefit specialty medication update bulletin – June 2025

Specialty medication program updates for UnitedHealthcare Commercial, Community Plan, Medicare Advantage and Individual & Family Plans

Specialty medical injectable medications added to Review at Launch					
Medication Name	HCPCs Code(s)	UHC Commercial	UHC Community Plan	UHC Medicare Advantage	UHC Individual & Family
Imaavy™ (nipocalimab-aahu)	J3490/J3590/C9399	X	X	X	X



Note: Medications added to Review at Launch may not yet be available in the marketplace.

To view the **UnitedHealthcare Commercial Plan** Review at Launch Medication List, visit UHCprovider.com > Coverage and Payments > Policies and protocols > For Commercial Plans > Medical & Drug Policies for UnitedHealthcare Commercial Plans > *Review at Launch for New to Market Medications – Commercial Medical Benefit Drug Policy* > [Review at Launch Medication List](#).

To view the **UnitedHealthcare Community Plan** Review at Launch Medication List, visit UHCprovider.com > Coverage and Payments > Policies and protocols > For Community Plans > Medical & Drug Policies for Community Plan > *Review at Launch for New to Market Medications – Community Plan Medical Benefit Drug Policy* > [Review at Launch Medication List](#).

For **UnitedHealthcare Medicare Advantage**, Review at Launch medications are added as Review at Launch Part B Medications in the *Medications/Drugs (Outpatient/Part B) Medical Policy*. To view the policy, visit UHCprovider.com > Coverage and Payments > Policies and protocols > For Medicare Advantage Plans > Medical Policies for Medicare Advantage Plans > *Medications/Drugs (Outpatient/Part B) – Medicare Advantage Medical Policy* > Supporting Information > [Other Examples of Specific Drugs/Medications](#).



To view the **UnitedHealthcare Individual & Family Plan** Review at Launch Medication List, visit UHCprovider.com > Coverage and Payments > Policies and protocols > For Individual Exchange Plans > Medical & Drug Policies for UnitedHealthcare Individual Exchange Plans > Review at Launch for New to Market Medications – Individual Exchange Medical Benefit Drug Policy > **Review at Launch Medication List.**

Updates to medication program requirements and drug policies – Effective Sept. 01, 2025						
Medication Name	HCPCS Code(s)	UHC Commercial	UHC Community Plan	UHC Medicare Advantage	UHC Individual & Family	Summary of Changes
Casgevy® (exagamglogene autotemcel)	J3392		X Maryland Only			<ul style="list-style-type: none"> Add prior authorization/notification Will be managed by Optum Transplant
Daxxify® (daxibotulinumtoxinA-lanm)	J0589		X Maryland Only			<ul style="list-style-type: none"> Add prior authorization/notification
Lyfgenia™ (lovotibeglogene autotemcel)	J3394		X Maryland Only			<ul style="list-style-type: none"> Add prior authorization/notification Will be managed by Optum Transplant
Pavblu™ (afibercept-ayyh) <i>Biosimilar to Eylea®</i>	Q5147		X Maryland Only			<ul style="list-style-type: none"> Add prior authorization/notification

UnitedHealthcare will honor all approved prior authorizations/notifications on file until the earlier of the end date on the authorization/notification or the date the member's eligibility changes. Upon prior authorization/notification renewal, the updated policy will apply.

Note: Certain specialty medical injectable drug programs and updates will not be implemented at this time for providers practicing in Rhode Island, with respect to certain commercial members, pursuant to the Rhode Island regulation: 230-RICR-20-30-14. UnitedHealthcare encourages providers practicing in Rhode Island to call in to confirm if prior authorization/notification is required. This exception does not apply to Medicaid and Medicare.

Specialty medical injectable medications added to Medication Sourcing for Outpatient Hospital Providers Only – UnitedHealthcare Commercial – Effective July 01, 2025		
Medication Name	HCPCS Code(s)	Specialty Pharmacy
Niktimvo™ (axatilimab-csfr)	J9038	Caremark (CVS Specialty)
Otufi® (ustekinumab-aaaz) <i>Biosimilar to Stelara®</i>	Q9999	Amber Specialty Pharmacy Optum Specialty Pharmacy



Pyzchiva® (ustekinumab-ttwe) <i>Biosimilar to Stelara</i>	Q9996, Q9997	Amber Specialty Pharmacy
Selarsdi™ (ustekinumab-aekn) <i>Biosimilar to Stelara</i>	Q9998	Amber Specialty Pharmacy
Steqeyma® (ustekinumab-stba) <i>Biosimilar to Stelara</i>	Q5099	Accredo Health Group Amber Specialty Pharmacy Caremark (CVS Specialty)
Wezlana™ (ustekinumab-auub) <i>Biosimilar to Stelara</i>	Q5137, Q5138	Optum Specialty Pharmacy
Yesintek™ (ustekinumab-kfce) <i>Biosimilar to Stelara</i>	Q5100	Accredo Health Group Amber Specialty Pharmacy Caremark (CVS Specialty)



Outpatient hospitals are required to obtain the medications listed in the [Medication Sourcing Protocol - Requirements to use a participating specialty pharmacy for certain medications document](#) from the indicated specialty pharmacies for distribution of these medications, unless otherwise authorized by us. When the specialty medication is obtained through the specialty pharmacy, the specialty pharmacy will bill us directly for these medications under the member's medical benefit. The facility administering the specialty medication is not to bill us for the medication obtained through the specialty pharmacy but may bill us for the administration of the medication to the member.

New and Updated Procedure Codes for Injectable Medications – Effective July 1, 2025

Centers for Medicare & Medicaid Services (CMS) has issued new procedure codes for certain injectable medications effective July 1, 2025. Correct coding rules dictate that assigned and permanent codes should be used when available. The injectable medications listed below will have new codes and may require prior authorization.

Note: Drugs with newly assigned CMS codes may not yet be available in the marketplace.

- **Aucatzyl®** (obecabtagene autoleucel) – Q2058
- **Hypavzi™** (marstacimab-hncq) – J7172
- **Imuldosa®** (ustekinumab-srlf) – Q5098
- **Lenmeldy™** (atidarsagene autotemcel) – J3391
- **Steqeyma** (ustekinumab-stba) – Q5099
- **Yesintek** (ustekinumab-kfce) – Q5100

